Efficacy and safety of HCP1102 capsule : A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial.

Inclusion:

• Age≥15
• Mild or moderate asthma patients with allergic rhinitis
• Patient who meet all criteria of rhinitis
• Patients understood the contents and purpose of this trial and signed informed consent form
• Patients who are capable and willing to write subject diary
• Patients who agree with maintain same environment during clinical trials

Exclusion:

• Nonallergic rhinitis
• Severe asthma
• Other pulmonary disease (pulmonary tuberculosis, COPD) except Asthma
• Medical history of hypertrophic cardiomyopathy, cancer, renal disease, Liver disease, cardiovascular disease, respiratory disease, endocrine disorder, CNS disorder that effect safety
• Medical history of gastrointestinal surgery or gastrointestinal disorders that effect drug absorption
• Alcohol abuse or Drug abuse
• Genetic factor of galactose intolerance or Lapp lactase deficiency or glucose-galactose malabsorption
• pregnant or breast-feeding women or men/women of childbearing age that they don't use contraceptives
• Patient who administered other investigational products within 30 days
• Current smoker Judged to be inappropriate for the study by the investigator after reviewing other reasons